Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day
February 05 2021 - 8:25AM
Business Wire
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced
that Tom Civik, President and Chief Executive Officer, and Helen
Collins, M.D., Executive Vice President and Chief Medical Officer,
are scheduled to participate in a fireside chat at the virtual
Guggenheim Healthcare Talks: Oncology Day on Friday, February 12,
2021 at 1:00 p.m. ET/10:00 a.m. PT.
Live audio webcast of the fireside chat will be accessible and
available for replay from the “Events & Presentations” section
of the Company’s website at:
http://investor.fiveprime.com/events.cfm. Five Prime will maintain
an archived replay of the webcast on its website for 30 days after
the conference.
About Five Prime Therapeutics
Five Prime is a clinical stage biotechnology company
relentlessly focused on rewriting cancer. By tackling the tough
scientific questions and untapped pathways, we aim to offer new
hope by developing novel, breakthrough therapies that have
potential to alter the course of disease in cancers with few
treatment options. This vision is what defines us and guides our
research, clinical development and partnerships. To build a better
tomorrow for people with cancer, we are teaming up with patients,
physicians, scientists, and industry partners to make a meaningful
difference in patients’ lives. Five Prime collaborates with leading
global pharmaceutical companies and has therapies in pre-clinical
and clinical development. For more information, please visit
www.fiveprime.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210205005070/en/
Martin Forrest VP, Investor Relations & Corporate
Communications Five Prime Therapeutics, Inc. 415-365-5625
martin.forrest@fiveprime.com Source: Five Prime Therapeutics,
Inc.
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Five Prime Therapeutics Inc (NASDAQ): 0 recent articles
More Five Prime Therapeutics, Inc. News Articles